## PGC Secondary or Cross-Disorder Analysis Proposal (v2.1, revised 05-2015)

Date	
Title	

Investigative Team. Underline PGC PI taking responsibility for all aspects of this proposal.

Name	Email	PGC group

Specific data access requested. Individual genotypes always require permissions. For summary results, no permission required for anything posted on <u>PGC downloads</u>. Permissions needed for all other summary result files (e.g., pre-publication, individual studies, M vs F, etc.)

Group	Individual genotypes	Summary results	Permission from group?	Version (e.g., MDD2, SCZ3)
ADHD				
ALZ				
AUT				
BIP				
ED				
MDD				
OCD/TS				
PTSD				
SCZ				
SUD				

A. Research Question, Goal, or SpecificAims				
Provide a brief description (e.g., 1 paragraph) describing the aims of the proposal and the research questions to be addressed.				
3. Analytic Plan				
Provide a brief description of the analyses to be performed to address the research questions lescribed above. Include relevant details e.g. phenotype definition, QC, analysis, plans to address population stratification and other confounders, power.				

C. Analytic Personnel
Indicate who will be responsible for performing the analyses.
<b>D. Resources Needed</b> Describe the resources needed to achieve the aims of the analysis, including variables needed, analytic support, and any other issues that may affect the feasibility of the plan.

E. Timeline	
Estimate time required to complete the plan and write a paper (should be $\leq$ 6 months)	).
F. Collaboration	
The following is the standard PGC policy about secondary analyses. Any deviation from	n this
policy needs to be described and justified, and could negatively impact the proposal.	T CITIS
PGC investigators who are not named on this proposal but who wish to substantively contrib	ute to the
analysis and manuscript may contact the proposing group to discuss joining the proposal.	are to the
G. Authorship	
This is an extremely important part of this proposal. Describe how authorship will be h	andled in
the manuscript resulting from this analysis. To avoid a revision, first review the author	ship policy
of the group(s) whose data you wish to analyze. Points to address:	
(a) are you following the authorship policies of the groups involved?	
<ul><li>(b) will there be a writing group and if so, who will be included?</li><li>(c) what groups or individuals will be listed as authors?</li></ul>	
(d) will PGC members not listed as named authors be listed at the end of the manus	script?
(e) will PGC members or groups be listed as "collaborators" on the PubMed abstra	ict page?
(f) how will funding sources be handled or acknowledged?	